Evidence map›Paper›PMID 42856677›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Antiviral Antibody Fc Dysfunction Is Linked to Increased IgG1 Fucosylation in Long COVID.

Rahul Ukey, Ioannis E Michailidis, Patricia Greenberg, Tracy Andrews, Sung Yun Jung, Haiyan Zheng, William Honnen, Abraham Pinter, Lawrence C Kleinman, Natalie Bruiners and 1 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rahul UkeyPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ.ORCID 0000-0002-0354-7496
Ioannis E MichailidisPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ.
Patricia GreenbergDepartment of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ.
Tracy AndrewsDepartment of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ.
Sung Yun JungDepartment of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX.
Haiyan ZhengBiological Mass Spectrometry Facility of Robert Wood Johnson Medical School and Rutgers, Rutgers University, Piscataway.
William HonnenPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ.
Abraham PinterPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ.
Lawrence C KleinmanDepartment of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Natalie BruinersPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ.
Maria Laura GennaroPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ.

Funding

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GROSS, RACHEL SHARON, HORWITZ, LEORA · 2021 to 2025
$651.0M
New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9M
The PreVAIL-kIds Common ProtocolR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ALLEN, CARL E, ANNAPRAGADA, ANANTH V · 2023 to 2023
$6.3M
COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to Predict SIck Children)R33HD105619 · NICHD · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GENNARO, MARIA LAURA, HORTON, DANIEL BENJAMIN · 2023 to 2023
$3.0M
Cohort and biomarkers for COVID-19 severity, natural history, and reinfectionR01AI158911 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI BARRETT, EMILY S, BLASER, MARTIN J · 2021 to 2023
$2.6M
Stanford Integrated Cardiovascular/Pulmonary Residency Research Training ProgramR38HL143615 · NHLBI · STANFORD UNIVERSITY · PI Michael Peter Fischbein, Marlene Rabinovitch · 2020 to 2026
$2.2M
NCATS NIH HHS UL1 TR003017NHLBI NIH HHS OT2 HL161847NHLBI NIH HHS R38 HL143615NIAID NIH HHS R01 AI158911NICHD NIH HHS R33 HD105593NICHD NIH HHS R33 HD105619
6 · The paper itself

Abstract

Background: Persistent SARS-CoV-2 antigen is a leading hypothesis for post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. Impaired Fc-mediated antiviral antibody function could contribute to inefficient clearance of infected cells and viral antigen despite preserved antibody levels. Therefore, we tested whether PASC is associated with altered Fcγ receptor-mediated antibody function and differences in IgG1 Fc fucosylation, a major regulator of Fc effector function. Methods: Serum samples from RECOVER-Adult participants with prior SARS-CoV-2 infection (99 PASC, 139 non-PASC) were analyzed for anti-SARS-CoV-2 spike receptor-binding domain (RBD) IgG and subclasses, FcγRIIIa- and FcγRIIa-mediated reporter activity as surrogate measures of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), anti-RBD IgG1 Fc glycosylation, and circulating fucose-modifying enzymes. Results: Despite higher anti-RBD IgG and IgG1 abundance, PASC sera showed lower ADCC- and ADCP-associated FcγR reporter activity, including after normalization for antibody abundance. Anti-RBD IgG1 showed greater fucosylation in PASC samples (30 PASC, 34 non-PASC). Serum FUCA2 was lower in PASC samples (24 PASC, 34 non-PASC), whereas FUCA1 and soluble CD16a levels did not differ between the two groups. Conclusion: PASC is associated with impaired antiviral IgG Fc function, increased IgG1 Fc fucosylation, and reduced circulating FUCA2, identifying a glycoimmune axis that may contribute to impaired Fc-dependent antigen clearance and represents a potentially targetable pathway in Long COVID.

Indexed as

antibody effector functionFcγRIgG1 Fc glycosylationPost-acute sequelae of SARS-CoV-2 infection (PASC)

Identifiers

PMID42856677
PMCPMC13648791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.